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Background
The genetic background of the Finnish population has
led to a unique epidemiology for some the rare hereditary
disorders. In particular the incidence of PKU-is very low,
less than 1:100000. Finland has screened only for conge-
nital hypothyroidism from cord blood since 1984. A pro-
posal to start a pilot study on screening with MS/MS
with the cost estimation of 1-3€/newborn necessitated a
Health technology assessment (HTA). In this article the
major problems encountered during the assessment pro-
cess and thereafter are presented.
Material and methods
The original HTA project started form identifying the pos-
sible disorders to be screened for Finland, evaluating the
possible costs of building up the screening organization,
cost-effectiveness, organizational and ethical consequences
[1,2]. The original documents from the HTA project and
from the national screening committee at the ministry of
social affairs and health were used.
Results
Lacking reliable data on incidence, natural course of the
possible disorders, sensitivity and specificity of the screen-
ing tests, effect of early diagnosis and early treatment
raised many ethical questions. It became evident that a
thorough ethical evaluation was needed to answer ques-
tions like “Can infants become the focus of research to
answer the unknown? When is it acceptable to screen for
many to find a few?”. Modeling a screening organization
does not guarantee that it will work in real life but the esti-
mated costs were 45€/newborn for finding 5-10 children
with a rare metabolic disorder per year in Finland. The
annual birth rate in Finland is approximately 56000.The
national screening organization has discussed the topic at
17 meetings during 2003-2012, the chairpersons and com-
mittee members have changed. Seminars and workshops
with content experts have been organized to answer the
identified critical questions, yet more information was
needed. A national pilot study was withdrawn; a local fea-
sibility study was conducted. An HTA report on PKU
screening when neither parent is of Finnish origin was
conducted in 2008 [3].
Conclusions
The original assumptions on costs were fictional. A con-
tinuous conversation with the screening committee and
the content experts has been necessary and understanding
the complexity and consequences of the decision increased
during the years. The ongoing changes in structuring
health and social care and the planned changes in legisla-
tion affect how national screening programs can be imple-
mented. Screening for metabolic disorders in newborn has
so far not yet been expanded.
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